key: cord-0891333-3hvlsrp3
authors: Kuo, Chia-Ling; Pilling, Luke C; Atkins, Janice L; Masoli, Jane A H; Delgado, João; Tignanelli, Christopher; Kuchel, George A; Melzer, David; Beckman, Kenneth B; Levine, Morgan E
title: Biological Aging Predicts Vulnerability to COVID-19 Severity in UK Biobank Participants
date: 2021-03-04
journal: J Gerontol A Biol Sci Med Sci
DOI: 10.1093/gerona/glab060
sha: b5fe5a900e0a33f8a51bf525c292a6dc4aadee04
doc_id: 891333
cord_uid: 3hvlsrp3

BACKGROUND: Age and disease prevalence are the two biggest risk factors for COVID-19 symptom severity and death. We therefore hypothesized that increased biological age, beyond chronological age, may be driving disease-related trends in COVID-19 severity. METHODS: Using the UK Biobank England data, we tested whether a biological age estimate (PhenoAge) measured more than a decade prior to the COVID-19 pandemic was predictive of two COVID-19 severity outcomes (inpatient test positivity and COVID-19 related mortality with inpatient test-confirmed COVID-19). Logistic regression models were used with adjustment for age at the pandemic, sex, ethnicity, baseline assessment centers, and pre-existing diseases/conditions. RESULTS: 613 participants tested positive at inpatient settings between March 16 and April 27, 2020, 154 of whom succumbed to COVID-19. PhenoAge was associated with increased risks of inpatient test positivity and COVID-19 related mortality (OR(Mortality)=1.63 per 5 years, 95% CI: 1.43-1.86, p=4.7×10 (-13)) adjusting for demographics including age at the pandemic. Further adjustment for pre-existing disease s/conditions at baseline (OR(M)=1.50, 95% CI: 1.30-1.73 per 5 years, p=3.1×10 (-8)) and at the early pandemic (OR(M)=1.21, 95% CI: 1.04-1.40 per 5 years, p=0.011) decreased the association. CONCLUSIONS: PhenoAge measured in 2006-2010 was associated with COVID-19 severity outcomes more than 10 years later. These associations were partly accounted for by prevalent chronic diseases proximate to COVID-19 infection. Overall, our results suggest that aging biomarkers, like PhenoAge may capture long-term vulnerability to diseases like COVID-19, even before the accumulation of age-related comorbid conditions.

A c c e p t e d M a n u s c r i p t general population samples 9 . The resulting AUCs were 70 to 80% but may not be generalizable to COVID-19 10 . A recent study used 98 variables (demographics, recent vital signs, COVID-19 testing status and symptoms, as well as pre-existing medical diagnoses) and 12,502 patients (9,931 training and 2,531 testing samples) with COVID-19 related visits to Massachusetts General Hospital emergency department and/or respiratory illness clinics (initiated for the pandemic) from March 7 to May 2, 2020, to predict an ordinal severity outcome within 7 days: i) no event, ii) hospitalized, iii) ICU care and/or mechanical ventilation, or iv) death, where the training results (AUC 0.76 for hospitalization, 0.79 for critical illness: ii, iii, or iv, and 0.93 for death versus others for each) were used to derive an acuity score for outpatient screening 11 .

In recent years, we have developed and widely validated several biomarkers of aging 12-14 that strongly predict morbidity and mortality risk, in both short-term (1 year) and long-term (25+ years) follow-ups 12, 14, 15 . Based on these observed trends, we hypothesize that biological aging, above and beyond chronological age, is a robust determinant of symptom severity following COVID-19 infection. We aimed to assess the risk and predictive performance of accelerated aging for COVID-19 severe infection using a biological age measure, named phenotypic age (PhenoAge). PhenoAge was previously trained using 42 biomarkers as inputs into a supervised machine learning model to predict all-cause mortality 12, 15 . We applied this measure to biomarker data from 2006 to 2010 of participants from a large community cohort, United Kingdom Biobank (UKB) 16, 17 . Combined with information on disease diagnoses updated to March 2020, we tested whether accelerated aging was predictive of COVID-19 severity based on mortality data and COVID-19 test results linked from the UK National Health Service (NHS) 18 .

A c c e p t e d M a n u s c r i p t

United Kingdom Biobank (UKB) 16, 17 is a volunteer community cohort, recruiting over 500,000 subjects between the ages of 40 and 70 during 2006 to 2010. We restricted analyses to participants attending baseline assessment centers in England, excluding those who died before March 16 , 2020 (first test date in the UKB COVID-19 test results). At recruitment (baseline), biological samples of participants were collected for biomarker assays. The disease status was confirmed based on self-reported doctor diagnoses at baseline or hospital admission records updated to March, 2020.

Also, the mortality data was used based on death certificates to October, 2020. These phenotypic data are linked to the UK national COVID-19 test results, currently from March 16 to December 21, covering the first peak of COVID-19 incidence.

Early testing in the United Kingdom was largely restricted to hospital in-patients with clinical signs of infection 18 

PhenoAge was developed based on mortality scores from the Gompertz proportional hazard model on chronological age and nine biomarkers, which were selected from 42 biomarkers by Cox penalized regression model for best predicting all-cause mortality as a surrogate of biological aging in the National Health and Nutrition Examination Survey III (NHANES III) 12 . Other methods can be used to derive biological age estimates from the set of biomarkers applied here. PhenoAge is more interpretable than the biomarkers given that it is expressed in units of years, on the same scale as chronological age. Therefore, it can be directly contrasted against chronological age to access accelerated aging. PhenoAge is proportional to 10-year mortality risk 12 

We tested associations of 1) age at the pandemic (set as March 16, 2020, the first COVID-19

test date in the data, a shift of age at baseline), 2) PhenoAge at baseline (10+ years prior), and 3) preexisting diseases or conditions with the two COVID-19 severity outcomes, using the logistic models below. A value of 5 suggests a participant is 5 years older than expected (faster ager), while a value of -5 suggests he/she is 5 years younger than expected (slow ager). Thus, we hypothesize that higher PhenoAgeAccel (faster biological aging) will be positively associated with COVID-19 severity.

A c c e p t e d M a n u s c r i p t

There is no implication that PhenoAge is a better predictor than the biomarkers in PhenoAge especially when the outcome is not all-cause mortality. For sensitivity analysis, we replaced PhenoAgeAccel in M6 with the biomarkers in PhenoAge to determine relative contributions of the biomarkers to associations with the two COVID-19 severity outcomes.

M7: age at the pandemic + pre-existing diseases or conditions to March 2020 + albumin + creatinine + glucose + ln(CRP) + lymphocyte percentage + mean corpuscular volume + RDW + alkaline phosphatase + white blood cell count where each biomarker was z-transformed to be in the same scale for the effect comparison with other biomarkers. We acknowledge that this model may be biased to overfitting in comparison to M6 since unlike PhenoAge for which the weighting of biomarkers was derived from an independent sample, these weights will be derived within the UKB sample for the outcome of interest.

The above models (M1-M7) were also adjusted for sex, self-reported ethnicity, and baseline UKB assessment center in England to account for geographic differences in the prevalence of COVID-19. The pre-existing diseases/conditions were mostly selected as those included in Atkins et al. 5 (ICD-10 codes in Table S1 ): dementia, type II diabetes, history of pneumonia, depression, atrial fibrillation, hypertension, COPD, chronic kidney disease, rheumatoid arthritis, coronary artery disease, history of delirium, stroke, asthma, previous falls/fragile fractures, osteoarthritis, and liver disease.

We estimated the proportions of mediated effects of included diseases (to March 2020) and comorbidities (number of diagnosed diseases) for the association between accelerated aging (1 if PhenoAgeAccel >0 and 0 if PhenoAge 0) and inpatient test positivity or COVID-19 related mortality, using participants free of the considered diseases at baseline, a logistic regression model for a binary dependent variable and a Poisson regression model for a count dependent variable (comorbidities), adjusting for age at the pandemic, sex, ethnicity, and assessment centers.

We also evaluated M1-M7 for predictive power by AUC using 10-fold cross validation.

Specificity, positive and negative predictive values were reported when the sensitivity was controlled A c c e p t e d M a n u s c r i p t at a desired level by manipulating the predicted probability threshold to predict who will be severely infected. All the statistical analyses were performed in R version 3.4.1. The mediation analysis was conducted using the 'mediation' R package 22 . A c c e p t e d M a n u s c r i p t

The mean duration between baseline blood draw and the onset of the pandemic, set as 3/16/2020, was 11.5 years with the standard deviation 0.8 years. Boxplots and violin plots for

PhenoAge acceleration by status of demographic, COVID-19 severity, or disease status at the pandemic ( Figure S1-S4 significantly associated with inpatient test positivity but not with COVID-19 related mortality likely due to a lack of power given the odds ratios were similar for both outcomes (Table S2) .

A c c e p t e d M a n u s c r i p t (Tables S4 and S5 ). Of note, the disease mediation effects are not additive as they likely share common mechanisms. Given that the mediation analyses are exploratory due to limited inpatient positives and COVID-19 related deaths, more research needs to be conducted to confirm any causal links.

Using samples with complete data to train M1-M7 models, the AUC was higher for COVID-19 mortality than that for inpatient test positivity (Figure 1 ). Using baseline and up-to-date disease diagnosis data significantly improved AUC compared to using baseline data only. The AUC was similar for models using more or less baseline data, i.e., M1 to M4, and was not substantially increased by baseline PhenoAge, additional to demographics and baseline disease states.

As shown in Figure 1 , the difference in PPV among models for either severity outcome (Table S3 ).

Higher PhenoAge was linked to COVID-19 severity with adjustment for chronological age.

The association was modestly reduced by prevalent diseases at baseline and decreased when disease states were updated to the start of the pandemic. Our mediation analysis results suggested that only ~20% of the association between accelerated aging a decade or more prior and increased COVID-19 severity was mediated by incident diseases (acquired over that period of time).

The association between age-adjusted PhenoAge and COVID-19 severity, with involvement of disease pathology, may be explained by mechanisms underlying accelerated aging by PhenoAge. In our recent genome-wide association study (GWAS) on PhenoAge acceleration, we observed enrichment for biological processes involved in immune system, cell function, and carbohydrate homeostasis 23 . A methylation clock (DNAmPhenoAge) trained using PhenoAge as a surrogate for biological age, instead of chronological age, has been shown to be associated with activation of proinflammatory, interferon, DNAm damage repair, transcriptional/translational signaling, and various markers of immunosenescence: a decline of naïve T cells and shortened leukocyte telomere length 12 .

Overall, this suggests that the accelerated biological aging profile captured by PhenoAge is largely characterized by accelerated inflammaging (chronic low-grade inflammation) 24 , whose underlying mechanisms may exacerbate COVID-19 symptoms. This is also supported by the observation that albumin and CRP more than a decade ago were associated with increased risk of inpatient test positivity.

While we modelled PhenoAge and PhenoAge biomarkers alternatively using exactly the same data, they have different indications in the context of COVID-19 severity. As we have emphasized in the Methods section that PhenoAge was pre-trained using a US cohort (NHANES III) to be a proxy of biological aging via the surrogate of all-cause mortality, it is expected to be a robust predictor for a A c c e p t e d M a n u s c r i p t wide range of age-related outcomes, hypothetically including COVID-19 severity, which is tested in this study. It should be noticed that PhenoAge is not a unique predictor for biological aging. Other sets of variables have been used to develop biological age predictors, as reviewed in the Introduction.

These variables may or may not have direct connection to biological aging. Therefore, it is less meaningful to discuss the contribution of each biomarker to the association between PhenoAgeAccel and COVID-19 severity. However, we acknowledge the importance of research on prognostic biomarkers for COVID-19 severity. Compared to biological age predictors, we tend to have a better understanding of biomarkers, which would suggest underlying mechanisms and potential interventions.

The case fatality rate of COVID-19 increases with chronological age, PhenoAge, and accumulation of chronic co-morbidities. There is therefore a potential that the effects of COVID-19 on mortality may be reduced by reversing/slowing the aging process. Drugs under development to slow the aging process may provide avenues for treating COVID-19 or reducing the risks associated with it. This is in-line with the geroscience framework and further supported by our previous work showing that people with younger biological ages are less prone to a plethora of diverse age-related diseases 25 . By intervening to slow aging, therapeutics may in turn reduce pathological burden as well as minimize the risks of diseases like COVID-19, which are exacerbated by aging and pathology. To date, a number of aging therapeutics are being considered, which target key pathways and hallmarks of aging-reducing insulin/IGF-1 signaling (rapamycin), removing senescent cells (senolytics), and/or improving insulin sensitivity (metformin). Increasing autophagy and reducing age-related inflammation are also emerging as key mechanisms targeted by these drugs 26 . Overall, our findings further substantiate the role of biological aging in the progression of COVID-19 and support the call for trials on longevity drugs to treat and/or prevent COVID-19 symptom severity and lethality.

The predictive performance for COVID-19 severity outcomes was significantly improved by basic demographics and recent disease states, compared to the prevalence of test positivity and mortality in the cohort. Adding current PhenoAge may further improve the performance as the variation of biological age in relative to chronological age increases with age; therefore, current A c c e p t e d M a n u s c r i p t

PhenoAge may be a more sensitive measure than PhenoAge at baseline for accelerated aging.

However, models to predict rare events like COVID-19 severity outcomes inevitably have low positive predictive values. In other words, people with predicted probabilities greater than a threshold are at higher risk than others for severe COVID-19 but the absolute risk remains low. This model or other improved models with additional input could be a useful tool for risk evaluation, which in combination with educational intervention may encourage behavioral changes and greatly reduce the fatality rate of COVID-19.

There are limitations to this study, which warrant acknowledgement. First, we did not include cancers in the analysis as the status of cancer (e.g., progressing vs. remission) is not available, which is strongly associated with mortality related to COVID-19 27 . Additionally, some participants are not old enough to develop late-onset diseases. As disease cases may be misclassified as non-disease cases, the disease odds ratio estimates were likely to be biased towards the null 28 . Also, clinical severity data is not available, but we used the mortality data to derive the severity outcome, COVID-19 related mortality with inpatient test-confirmed COVID-19. Lastly, the UKB sample is known to be healthier than the general population 29 ; however, risk factor associations are usually generalizable 30 .

In conclusion, PhenoAge more than a decade ago prior to the pandemic was associated with COVID-19 severity. Our analysis suggested that this acted partly through disease pathology.

Accelerated aging by PhenoAge has previously reported to be largely characterized by inflammaging 24 

CLK and MEL designed the study. JLA, LCP, and CLK processed the data. CLK performed the data analysis. All the authors contributed to the manuscript and approved the final version.

MEL is named on patent applications for epigenetic clocks and holds licenses for the clocks she has developed. MEL also serves as the Bioinformatics Advisor for Elysium Health.

A c c e p t e d M a n u s c r i p t M a n u s c r i p t A c c e p t e d M a n u s c r i p t M a n u s c r i p t A c c e p t e d M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t 

An interpretable mortality prediction model for COVID-19 patients

Severe outcomes among patients with coronavirus disease 2019 (COVID-19) -United States

Ethnicity, and Age Trends in Persons Who Died from COVID-19 -United States

Characteristics of Persons Who Died with COVID-19 -United States

ApoE e4e4 genotype and mortality with COVID-19 in UK Biobank

Comorbidity and Its Impact on 1590 Patients with Covid-19 in China: A Nationwide Analysis

COVID-19 infection in Italian people with diabetes: Lessons learned for our future (an experience to be used)

Prediction models for diagnosis and prognosis of covid-19 infection: Systematic review and critical appraisal

Comparison of Hospitalized Patients With ARDS Caused by COVID-19 and H1N1

CoVA: An Acuity Score for Outpatient Screening that Predicts Coronavirus Disease

An epigenetic biomarker of aging for lifespan and healthspan

DNA methylation-based biomarkers and the epigenetic clock theory of ageing

Modeling the rate of senescence: Can estimated biological age predict mortality more accurately than chronological age?

A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study

An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age

The UK Biobank resource with deep phenotyping and genomic data

Dynamic linkage of COVID-19 test results between Public Health England's Second Generation Surveillance System and UK Biobank

UK Biobank biomarker panel

UK Biobank Haematology Data Companion Document

Mediation: R package for causal mediation analysis

Genetic associations for two biological age measures point to distinct aging phenotypes

Inflamm-aging. An evolutionary perspective on immunosenescence

Geroscience and the Coronavirus Pandemic: The Whack-a-Mole Approach is not Enough

The quest to slow ageing through drug discovery

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Logistic regression when the outcome is measured with uncertainty

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t